ArticleJournal of translational medicine2026
The therapeutic potential of pirfenidone in alleviating fibrosis and restoring ovarian function in a novel ovarian endometriosis mouse model.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian endometriosis (OEMs) is a primary cause of female infertility and is driven primarily by fibrosis, which disrupts the ovarian follicular microenvironment. Pirfenidone (PFD), an FDA-approved antifibrotic drug, holds promise for treating OEMs, but its efficacy and underlying mechanisms in a relevant in vivo model remain unexplored.
methodsA novel mouse model of OEMs was surgically induced. Model mice were randomized to receive either PFD (200 mg/kg every 2 days, n = 20) or vehicle (n = 20) for 24 days. We assessed lesion size and weight, fibrosis via Masson’s trichrome staining and α-SMA immunohistochemistry (IHC), ovarian function through follicle-stimulating hormone receptor (Fshr) IHC and quantitative PCR, and granulosa cell status via Ki67 IHC and TUNEL assays. An unbiased label-free quantitative proteomic analysis was performed to elucidate the mechanism, with key pathways validated by Prussian blue staining and Western blotting. Statistical significance was determined via Student’s t test.
resultsThe OEMs exhibited characteristic cysts, extensive fibrosis (increased α-SMA and collagen deposition, p < 0.05), impaired fertility, and disrupted ovarian function (downregulated Fshr, reduced granulosa cell proliferation, and increased apoptosis, p < 0.05). PFD treatment significantly reduced lesion size, weight, and fibrosis (p < 0.05) and restored the expression of markers of ovarian reserve and folliculogenesis (p < 0.05). Proteomics revealed 554 differentially expressed proteins. PFD downregulated pathways involved in extracellular matrix (ECM) organization and inflammation and upregulated proteins related to iron ion transport and ferroptosis. These findings were confirmed by a significant reduction in ferric iron deposition (p < 0.05) and collagen I protein expression (p < 0.05) in the PFD group.
conclusionsPirfenidone has strong therapeutic potential for treating ovarian endometriosis by simultaneously alleviating fibrosis and restoring ovarian function. Its efficacy is mediated through a novel mechanism of modulating iron homeostasis and the ferroptosis pathway, alongside its known antifibrotic actions. Our findings provide a compelling rationale for repurposing pirfenidone as a disease-modifying treatment for OEMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.